



ENADA®

Extends Life-Span of Cells and Organs

ENADA

the only real Anti-Ageing product



What is ENADA – NADH ?

What is Anti-Aging ?



N. A. D. H.

- **N**icotinamide
- **A**denin
- **D**inucleotide
- **H**ydride
- also known as reduced
- **C o e n z y m e - 1**

N A D H

**is the
biological form of
HYDROGEN**

The Rocket Fuel is :

Hydrogen + Oxygen = Explosion + Water

The Cell Fuel is:

NADH + Oxygen = Energy + H₂O + NAD


NADH can be regarded as
the „human rocket fuel“

N A D H

**occurs in
every living cell**

NADH

***concentrations
in human
organs
and tissues***




Heart

90 [mg/kg tissue]



Brain

40 [mg/kg tissue]



Muscles

50 [mg/kg tissue]


Liver

40 [mg/kg tissue]



Erythrocytes

8 [mg/kg tissue]



The Mitochondrion Energy Plant
Adapted from *Energy and Defense* by Prof. Gian Paolo Littarru
Pub: Casa Editrice Scientifica Internazionale, Rome Italy.

Biological functions of **ENADA**

- Fuel for cellular energy production
- Essential for cell and DNA repair
- Powerful Antioxidant
- Enhancer of immune system



ENADA is a very sensitive
substance and easily
degraded
by oxygen, heat, light and
acids

In order to make NADH
bioavailable it has to be
stabilized and transformed into
an **orally absorbable** form

ENADA[®]

The only **stabilized**
food grade
oral absorbable form of
N.A.D.H.

51 patents for
ENADA[®]
have been issued
worldwide

(7 formulation and 44 application patents
5 more patents are pending)



US005654288A

United States Patent [19]
Birkmayer

[11] **Patent Number:** **5,654,288**
[45] **Date of Patent:** **Aug. 5, 1997**

[54] **STABLE NADH AND NADPH
COMPOSITIONS FOR SUBLINGUAL
ADMINISTRATION**

0 496 479 B1 7/1992 European Pat. Off. .
92/0275 12/1992 South Africa .

OTHER PUBLICATIONS

South African Patent 92/0275 is an English language counter-
part of EPO 0 496 479 B1.

[75] **Inventor:** **Joerg G. D. Birkmayer**, Vienna,
Austria

[73] **Assignee:** **Birkmayer Pharmaceuticals, Inc.**,
New York, N.Y.

Primary Examiner—Theodore J. Criares
Attorney, Agent, or Firm—Kenyon & Kenyon

[21] **Appl. No.:** **632,373**

[22] **Filed:** **Apr. 10, 1996**

[57] **ABSTRACT**

NADH and/or NADPH is applied topically to the skin. It was surprising and totally unexpected to discover that NADH and NADPH are absorbed by the skin and penetrate the cutis to be taken up by the skin cells, where they stimulate certain enzymes which are essential for the energy production of the cells. The enzymes stimulated are principally the mitochondrial enzymes. The NADH and/or NADPH can be incorporated into a skin compatible cream, lotion or cosmetic. Liposomes are ideal vesicles for carrying the NADH and/or NADPH into the skin. In other embodiments of the invention, NADH and/or NADPH is administered nasally (e.g., as a liquid spray or a powder spray through the nostrils), sublingually (e.g., in the form of uncoated tablets inserted underneath the tongue) and rectally (e.g., in the form of suppositories) for known therapeutic effects (e.g., the treatment of Parkinson's disease).

Related U.S. Application Data

[62] Division of Ser. No. 373,147, Jan. 17, 1995, Pat. No. 5,538,953.

[51] **Int. Cl.**⁶ **A61K 31/70**

[52] **U.S. Cl.** **514/52; 514/959**

[58] **Field of Search** 514/52, 959

[56] **References Cited**


U.S. PATENT DOCUMENTS

4,970,200 11/1990 Berkmyer et al. 514/52
5,019,561 5/1991 Birkmayer 514/52
5,332,727 7/1994 Birkmayer 514/52

FOREIGN PATENT DOCUMENTS

2057456 7/1996 Canada .

9 Claims, No Drawings

(19)  **Europäisches Patentamt**
European Patent Office
Office européen des brevets



(11) **EP 0 697 859 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
04.06.1997 Bulletin 1997/23

(51) Int. Cl.⁶: **A61K 9/36**, A61K 9/38,
A61K 31/70, A61K 9/20,
A61K 9/28

(21) Application number: **94914734.2**

(86) International application number:
PCT/US94/03290

(22) Date of filing: **25.03.1994**

(87) International publication number:
WO 94/25007 (10.11.1994 Gazette 1994/25)

(54) **STABLE, INGESTABLE AND ABSORBABLE NADH AND NADPH THERAPEUTIC COMPOSITIONS**

STABILE, ORALE UND ABSORBIERBARE THERAPEUTISCHE ZUSAMMENSETZUNGEN VON NADH UND NADPH

COMPOSITIONS THERAPEUTIQUES PERORALES, STABLES ET ABSORBABLES DE NADH ET DE NADPH

(84) Designated Contracting States:
**AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL
PT SE**

(72) Inventor: **BIRKMAYER, Joerg G.D.**
A-1180 Vienna (AT)

(30) Priority: **29.04.1993 US 55049**

(74) Representative: **Wibbelmann, Jobst, Dr., Dipl.-
Chem. et al
Wuesthoff & Wuesthoff,
Patent- und Rechtsanwälte,
Schweigerstrasse 2
81541 München (DE)**

(43) Date of publication of application:
28.02.1996 Bulletin 1996/09

(73) Proprietor: **Birkmayer Pharmaceuticals, Inc.**
New York, NY 10118 (US)

(56) References cited:
US-A- 4 970 200

发明专利证书

发明名称: 稳定、可食、易吸收的NADH和NADPH治疗组合物

发明人: 乔格·G·D·伯克迈耶

专利号: ZL 94 1 91939.0 国际专利主分类号: A61K 9/36

专利申请日: 1994 年 3 月 25 日

专利权人: 美国伯克迈耶

授权公告日: 2001 年 10 月 10 日

证书号 第 74558 号



本发明经过本局依照中华人民共和国专利法进行审查, 决定授予专利权, 颁发本证书并在专利登记簿上予以登记。专利权自授权公告之日起生效。


本专利的专利权期限为二十年, 自申请日起算。专利权人应当依照专利法及其实施细则规定缴纳年费。缴纳本专利年费的期限是每年 3 月 25 日前一个月内。未按照规定缴纳年费的, 专利权自应当缴纳年费期满之日起终止。

专利书记载专利权登记时的法律状况。专利权的转移、质押、无效、终止、恢复和专利权人的姓名或名称、国籍、地址变更等事项记载在专利登记簿上。

专利号 

局长 王景川





特 許 証

特 許 第 2 5 3 3 7 0 9 号

平成03年 特 許 願第345766号

発 明 の 名 称 体 力 増 強 剤

特 許 権 者 オーストリア国 1090 ヴィエン シュヴァルツシュパニエルシュトラッセ 15
 国 籍 オーストリア国
 ユルク ビルクマイヤー

発 明 者 ユルク ビルクマイヤー
 ヴァルター ビルクマイヤー

この発明は、特許するものと確定し、特許原簿に登録されたことを証する。

平成 8年 6月27日

特 許 庁 長 官

清 川 佑



ENADA[®]

is marketed as a

n u t r i t i o n a l

s u p p l e m e n t



The Original New Packaging Design





ENADA[®] NADH

has been marketed as a
nutritional supplement
in the U.S.
since 1995



What is Aging ?

- Aging at the organ level
- Aging at the cellular level




Aging at the organ level

- **By limited blood (oxygen) supply**
- **by organ damaging substances:**
 - Alcohol – Liver
 - Smoking – Lung
 - Blood pressure medication – Brain
 - Cholesterol lowering drugs – Muscle
 - Cytostatic drugs - Heart

Consequence: Improve blood circulation (by physical exercise) and avoid toxins and drugs

Decline of physiological functions with age





Aging at the cellular level

- **Energy production declines with aging of the cell**
- **If the energy production of the cell declines below a certain threshold the cell will die**

Consequence: Keep energy production of the cell high



Why does energy production in a cell decline ?

Influences of factors

- (a) Inside the cell
- (b) Outside the cell

Intra-cellular factors : Oxidation, Free radicals, defect enzymes

Extra-cellular factors: Radiation, UV-Light and chemical Toxines

Metabolic and Energetic Changes During Apoptosis in Neural Cells

- J.C.Mills, D.Nelson, M.Erecinska and R. Pittman
- Journal of Neurochemistry (1995)
- These cells , upon exposure to stimuli that cause single-stranded DNA breaks, experience a large increase in poly (ADP-ribose) polymerase activity, which leads to depletion of cellular NADH
- **The loss of NADH is thought to lead to ATP depletion, which, in turn, leads to cells death.**



If a cell is already damaged
can we repair it
to full functionality ?

Yes,
we can by
ENADA


- **ENADA protects cells from damage by toxic agents such as doxorubicin and cisplatin used for chemotherapy of cancer**
- **ENADA promotes cell damage repair. Altered or damaged cells can be repaired to gain full functionality.**

- Cisplatin, one of the most frequently used agent for cancer treatment causes damages of cells (cancerous as well as normal ones) by destructing the cell membrane, the mitochondria and the nucleus.
- Preincubation of the cells with **ENADA** prevents the severe sometimes fatal changes induces by Cisplatin.
- Already altered and damaged cells can be restored to full functionality by incubating the cells with **ENADA**.

The Reduced Coenzyme Nicotinamide Adenine Dinucleotide (NADH) repairs DNA damage of PC12 cells induced by doxorubicin

JR Zhang, K.Vreko, K.Nadlinger. D.Storga
GD.Birkmayer and G.Reibnegger

J.Tumor Marker Onco.13, 5-17 (1998)



G. Birkmayer J. Zhang D. Storga K. Nadlinger

J.Zhang , Professor of Clinical Oncology at the University of Guangzhou (Canton) in China, performed all the DNA repair studies

The Reduced Coenzyme Nicotinamide Adenine Dinucleotide (NADH) Prevents Hepatic Cells from Apoptosis by Mitochondria dependant signalling Pathway

Meng XU, Jiren Zhang

Int. Journal of Modern Cancer
Therapy, 3, 38-41 (2000)

The Cytoprotection of Nicotinamide Adenine Dinucleotide (NADH) in the Mitochondria Regulation Mechanism*

Xu Meng, Zhang Jiren¹, Sarah SC Hui²

Department of Oncology, Nan Fang Hospital, The First Military Medical University, Guangzhou 510515, ¹Department of Oncology, Zhu Jiang hospital, ²School of Traditional Chinese Medicine, The University of Hong Kong, Hong Kong SAR, P.R. China

*The study was supported by a grant from SPACE of the University of Hong Kong

NADH is an essential component of enzymes for many metabolic reactions and energy production in cell. Mitochondria are well known to have a critical function in energy metabolism and damage to mitochondria has been related to apoptosis. Cytoprotection of NADH in apoptotic damage induced by Cisplatin (DDP) was explored to clarify the mechanism of mitochondria regulation pathway. Laser scanning confocal microscope was employed to detect mitochondria membrane potential $\Delta\psi_m$ with fluorescent probe R123, intracellular free Ca^{2+} value with probe Flu-3-AM, pH value with probe SNARF-1-AM and reduced oxygen species (ROS) value with probe H_2DCF in hepatocytes. The expression of cytochrome c and poly (ADP-ribose) polymerase (PARP) protein was detected by Western blot. Mitochondrial oxidative phosphorylation was measured polarographically by determining oxygen consumption rate state 3 and state 4, respiratory control rate (RCR) and ADP/O ratio. Compared with the group of control, in the group of DDP the fluorescence intensity of R123, Flu-3/AM, SNARF-1-AM and H_2DCF was raised obviously, which indicated that the reduction of mitochondria membrane potential, the improvement of intracellular Ca^{2+} and ROS value was kept. In the group of control, the expression of cytochrome c was released from mitochondria matrix to cytoplasm in the group of DDP and cytochrome c was not released in the group of NADH/DDP. 113 kDa PARP was detected in the group of control, but in the group of DDP PARP was broken into 89 kDa fragment. PARP kept integrated in the group of NADH/DDP. Compared with the group of control, the value of S_3 , RCR and ADP/O reduced more than 38%, 35% and 40% in the group of DDP. There was a significant difference between the group of NADH/DDP and DDP. The change of S_3 and mitochondria RCR reduction resulted in hepatocyte injury induced by DDP. NADH could prevent DDP-induced mitochondria impairment. Improving mitochondrial function represents a novel therapeutic strategy in cytoprotection of chemotherapy.

ISSN 1007-9327 CN 14-1219/R World J Gastroenterol 2003 Aug;9(8):1781-1785

X-ray induced L02 cells damage rescued by new anti-oxidant NADH

Fa-Quan Liu, Ji-Ren Zhang

Fa-Quan Liu, Ji-Ren Zhang, Department of Oncology, Zhujiang Hospital, First Military Medical University, Guangzhou 510282, Guangdong Province, China

Supported by Healthcare Research Fundation of the Tenth Five-Year Plan of PLA, No, 01MA138

Correspondence to: Fa-Quan Liu, Department of Oncology, Zhujiang Hospital, First Military Medical University, Guangzhou, 510282, China. liufaquan@163.net

Telephone: +86-20-85143202 Fax: +86-20-85143200

Received: 2002-08-06 Accepted: 2002-10-18

Abstract

AIM: To explore molecular mechanism of nicotinamide adenine dinucleotide (NADH) antagonization against X-ray induced L02 cells damage.

METHODS: L02 liver cells were cultured in RPMI 1640, exposed to X-ray irradiation and continued to culture in the presence or absence of NADH. Cellular viability was analyzed by routine MTT methods. The percent age of apoptotic cells and positive expressions of p53, bax and bcl-2, fas, fasL proteins were determined by FCM. Level of intracellular ROS was determined by confocal microscope scanning. Morphological change was detected by scanning electron micrograph.

RESULTS: The viability of L02 cells was decreased with increasing dose of X-ray irradiation. NADH could not only eliminate the apoptosis induced by X-ray irradiation, but also up-regulate expression of bcl-2 protein and down-regulate expression of p53, bax, fas and fasL proteins ($P < 0.05$). At the same time, NADH could reduce level of intracellular ROS in radiated L02 cells.

CONCLUSION: NADH has marked anti-radiation effect, its mechanism may be associated with up-regulation of bcl-2 expression and down-regulation of p53, bax fas and fasL expression, as well as decline of intracellular ROS. However, further investigation of its mechanism is worthwhile.

Liu FQ, Zhang JR. X-ray induced L02 cells damage rescued by new anti-oxidant NADH. World J Gastroenterol 2003; 9(8): 1781-1785

<http://www.wjgnet.com/1007-9327/9/1781.asp>



What is Anti-Aging ?

- Repair of damaged cells and tissues
- Increase of energy production in a cell
- Extend life-span of cells, tissues and organs





Can we increase the energy
production in a cell ?

Yes,
we can by
ENADA



Microscopic Picture of isolated heart cells





ATP is the abbreviation for **Adenosin-Tri-Phosphate**

ATP is a substance with a
high energy content in the molecule.

ATP is used by the cell for all
energy - consuming production processes




When isolated heart cells are incubated with ENADA (ENADA is outside the cell) , the **ATP** concentration inside the heart cells **increases**.

In other words, these heart cells do have more **ATP- energy**.

Hence, they can function better and can **live longer**.

ATP concentration of heart cells
before (green bar) & after (red bar) incubation
with **ENADA NADH**




**ENADA N A D H-supplementation
decreases pinacidil-primed $I_{K(ATP)}$ in
ventricular cardiomyocytes by
increasing intracellular ATP**

Pelzmann B, Hallström S, Schaffer P, Lang
P, Nadlinger K, Birkmayer GD, Vrecko C,
Reibnegger G and Koidl B

. Brit. J. Pharm. 2003 139, 749-754

Vitality of heart cells with and without ENADA NADH



Heart cells in the presence of ENADA NADH



This sensational new discovery has enormous implications for protection of the heart and other organs.

If cells live longer, all organs and the entire organism live longer.

In other words, **ENADA** has a - scientifically documented - **anti-aging effect.**



Richard M. Rosati
Direct 212.908.6472
rrosati@kenyon.com

One Broadway
New York, NY 10004-1050
212.425.7200
Fax 212.425.5288

February 3, 2003

VIA DHL COURIER

Dr. George D. Birkmayer
Labor Birkmayer & Medinfo Ltd.
Schwarzpanierstrasse 15
A-1090 Viena, Austria

Re: New U.S. Patent Application
METHOD OF PROLONGING THE LIFE-SPAN OF
LIVING CELLS USING NADH, NADPH AND ADP-RIBOSE
Our Ref. 1642/58

Dear George:

We wish to advise you that the above-identified application was filed on December 27, 2002 under Serial No. 10/330,973.




What about other human cells ?

Can their life-span be extended by
ENADA ?

**Yes,
it can**



Vitality of red blood cells with and without ENADA NADH



Red blood cells in the presence of ENADA NADH live much longer / with vitality and can be kept much longer for



Extension of the expiring date of blood donations by NADH

Blood for transfusion can only be stored
for 6 weeks by law

In the R&D department of Birkmayer
Laboratories it was discovered , that
blood can be kept 12 weeks or even
longer by addition of ENADA NADH

Economic implication of this findings:

1. The Austrian Red Cross sells 5 million blood bags per year for 300 million Dollars
2. One third of the blood bags have to be discarded because of the expiring date of 6 weeks.
3. If the Red Cross can use only 50% of the discarded blood it can make additional 50 (fifty) million Dollars only in Austria.



ENADA[®] NADH

**boosts cellular ATP energy
also in human subjects**



Can we measure the increase
ATP energy by
ENADA[®] NADH
in human subjects ?

Yes , we can by a new blood test
developed in our laboratory

ENMA®

A - patented - new blood test
for the determination
of the energy status

Developed by Birkmayer Laboratories, Vienna, Austria
www.birkmayer.com

What is the **ENMA** Test ?

Extracellular

NADH

Metabolization

Assay

How does the **ENMA** test work?

The **ENMA** test measures
how much *N.A.D.H.*
is metabolized
by blood cells.



The **N.A.D.H.** metabolization rate of blood cells is indirectly related to the ATP (energy) content of blood cells.¹⁾

1) Nadlinger et al. Biochim. Biophys. Acta 1573: 177-182 (2002)

Hence if blood cells have a low
ATP (energy) content
they metabolize a lot of
N.A.D.H.



ELSEVIER

Biochimica et Biophysica Acta 1573 (2002) 177–182



www.bba-direct.com

Extracellular metabolisation of NADH by blood cells correlates with intracellular ATP levels

Karl Nadlinger*, Wilhelm Westerthaler, Danijela Storga-Tomic, Jörg G.D. Birkmayer

Department of Research and Development, Birkmayer Laboratories, Schwarzschanierstr. 15, A-1090 Vienna, Austria

Received 26 April 2002; received in revised form 20 August 2002; accepted 4 September 2002

Abstract

A new assay allowing quantitation of extracellular NADH metabolisation by intact blood cells was compared with the intracellular ATP/ADP ratio of these cells. The sensitivity, reproducibility and NADH specificity of this assay were determined. The diagnostic potential of this test was examined in a study with highly conditioned athletes. NADH consumption was measured before and immediately after maximum aerobic performance as well as 1 day later and was compared with the ATP/ADP level in these blood cells. A significant decline of cellular energy after aerobic performance was detected with both approaches to a similar extent ($P < 0.01$). However, the extracellular NADH metabolisation assay (ENMA) is more convenient to perform than the determination of intracellular ATP/ADP. Due to its easy and versatile handling, a huge array of possible applications like monitoring the training efficiency of athletes, the fitness of senior citizens or the recovery from disease may be envisioned.

© 2002 Elsevier Science B.V. All rights reserved.

Keywords: NADH; ATP; Blood test; Sports

The **ENMA** test
has received
world wide patents



US006383771B1

(12) **United States Patent**
Birkmayer

(10) **Patent No.:** **US 6,383,771 B1**

(45) **Date of Patent:** **May 7, 2002**

(54) **ENZYME-BASED ASSAY FOR
DETERMINING EFFECTS OF EXOGENOUS
AND ENDOGENOUS FACTORS ON
CELLULAR ENERGY**

(75) **Inventor:** **Georg D. Birkmayer**, Vienna (AT)

(73) **Assignee:** **Birkmayer Pharmaceuticals**, New
York, NY (US)

(*) **Notice:** Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 76 days.

(21) **Appl. No.:** **09/631,692**

(22) **Filed:** **Aug. 3, 2000**

Related U.S. Application Data


Reichmann, et al., Respiratory Chain and Mitochondrial
Deoxyribonucleic Acid in Blood Cells from Patients with
Focal and Generalized Dystonia, Movement Disorders,
1994, 9(6), 597-600.

Mitzkat, et al., Enzyme Patterns of the Energy-Linked
Metabolism in Blood Cells of Human Diabetics, Hormone
and Metabolic Research, 1972, 4(2), 107-110.

Ramakrishna, et al., Influence of Cerebral Ischemia and
Post-Ischemic Reperfusion on Mitochondrial Oxidative
Phosphorylation, J. Bioenerg. Biomembr., 1990, 22(1),
61-80.

Primary Examiner—Jean C. Witz

(74) *Attorney, Agent, or Firm*—Kenyon & Kenyon

(19)  **Europäisches Patentamt**
European Patent Office
Office européen des brevets



(11) **EP 0 911 417 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
28.08.2002 Bulletin 2002/35

(51) Int Cl.7: **C12Q 1/26, C12Q 1/32,**
C12Q 1/25

(21) Application number: **98119764.3**

(22) Date of filing: **22.10.1998**

(54) **Enzyme-based assay for determining effects of exogenous and endogenous factors on cellular energy production**

Auf Enzym-gegründetes Assay zur Bestimmung der Wirkung von exogenen und endogenen Faktoren auf Zellenergie-Bildung

Test enzymatique pour déterminer les effets d'agents exogènes et endogènes sur la production d'énergie cellulaire


The **ENMA** test
was developed
to measure the
effect of
„energy increasing“
substances
in particular
that of
ENADA – N.A.D.H.



People with a high energy level
(athletes), need less NADH

People with a low energy level
(old or sick people),
need a lot of NADH

NADH metabolization of blood from people with increasing age



Older people metabolize much more NADH as they need more ATP energy




Marathonrunners before the race
have a high energy level, hence
they metabolize
little **N.A.D.H.**

Marathonrunners after the race
have a low energy level,
hence they metabolize
much **N.A.D.H.**



NADH – metabolization by blood from marathon runners



- The NADH which is not metabolized reflects the ATP content (energy-level) of the blood cells.

■ **Start**
■ **Finish**

Before the start the blood of the runners metabolizes only 20% of the NADH added, because the runners have enough ATP (energy) .

After the run the blood metabolizes 85% of the NADH added, because the ATP (energy) was used up during the marathon run.

On the effect of **ENADA – N.A.D.H.** with marathon runners

- Double blind placebo controlled cross-over study
- Group-1 were taking **ENADA –N.A.D.H.**
30 mg per day for 4 weeks
- Group-2 were taking Placebo pills
- The **ENMA** test was performed before start, after the run and 24 hours after the run.

On the effect of *ENADA – N.A.D.H.* with marathon runners


Results:

- The runners had a low NADH metabolization rate (= high ATP-energy level) before the race and a high NADH metabolization rate (=low ATP-energy level) after the marathon run.

The runners taking *ENADA* had a lower NADH metabolization rate (=higher ATP-energy level) than the runners taking the placebo pills.

- These results provide scientific proof that *ENADA-N.A.D.H.* increases cellular energy.

ENMA - test with marathon runners after intake of **ENADA – N.A.D.H.**





Applications of the **ENMA** test (1)

- Testing of energy enhancing substances
- Testing of „energy drinks“
- Testing of anabolic substances
- Controlling the training of athletes
- Controlling the energy level of elderly



Applications of the **ENMA** test (2)

- Testing the energy level of sick people
- Testing the energy level before and after medical treatment (surgery, radiation, chemotherapy etc.)
- Testing of energy level after rehabilitation (coronary heart disease, lung disease etc.)



ENADA[®] - NADH

and

Athletic performance



ENADA[®] - NADH

and

Athletic performance

7 % more muscular energy

Higher oxygen supply for the muscle

Lower lactate levels

Better performance on spiroergometry



ENADA® - NADH

and

Cognitive performance




Study shows: **NADH** alleviates symptoms of cognitive impairment caused by sleep deprivation

- Where was the study performed:
2001 at Cornell University New York, Publication in print
- How: Double-blind, placebo controlled study with middle-aged healthy individuals:
 - Subjects were kept awake one day and one night (24 hrs) ; one group took placebo in the morning after 24 hours of sleep deprivation,
 - the other group **ENADAlert (quick acting NADH)**
 - At day 1 in the morning and on the next day in the morning (after 24 h sleep deprivation) tests for visual perception mathematical problem solving capability and reaction time.




Visual Sequence Comparison Performance as measured by Cog-Screen®



The performance with NADH (after 24 hrs without sleep) was 3 points better than at base line (after a full night sleep)



Mathematical problem solving skills as measured by Cog-Screen®



The performance with NADH (after 24 hrs without sleep) was 0.7 points better than at base-line (after a full night sleep)



The Sensational Results



The subjects taking
ENADA - NADH
showed higher alertness
faster reaction-time and
better visual perception
after 24 h of sleep deprivation than
the day before
after a full night sleep.

After a press conference by Cornell University
reports of these sensational results were shown by :

ABC: „Good morning America“

CNN, Fox News

Reports were printed also in:

„NEWSWEEK“

„Wall Street Journal“

Effectiveness of NADH in Alleviating Effects of Sleep Deprivation in Healthy Middle-Aged Adults*

Moline ML, Rebeta JL, Flye BL, Zendell SM, Broch L, Ford T, Zak R, Kay GG (2)

- (1) Sleep-Wake Disorders Center, Department of Psychiatry, New York Presbyterian Hospital-Weill Medical College of Cornell University
- (2) Department of Neurology, Georgetown University School of Medicine

STUDY ABSTRACT

Aims: Sleep deprivation affects cognitive performance and quality of life. It impacts otherwise healthy individuals who cross time zones, work shifts, or have certain sleep, psychiatric, or medical disorders. Despite manufacturers' claims, few over-the-counter substances have been shown in rigorously designed studies to improve daytime alertness following sleep deprivation.

We tested the ability of oral stabilized NADH (ENADAlert®, a nutritional supplement) to improve alertness, mood, and performance on cognitive tasks in middle-aged subjects after one night of total sleep deprivation. NADH has been shown to increase subjective measures of energy in Chronic Fatigue Syndrome¹. NADH has also been shown to reduce the effects of jet lag on cognitive performance and sleepiness².

Methods: A double blind, placebo-controlled, randomized crossover study involving 25 healthy men and women ages 40-59 was conducted. Subjects were screened for medical, psychiatric, and sleep disorders and then underwent baseline cognitive assessment using a computerized battery (described below). On the baseline test day, subjects consumed sublingual placebo and had electrodes placed to simulate experimental conditions. They returned for one night of enforced, polygraphically-monitored wakefulness followed by morning consumption of sublingual NADH (ENADAlert 20 mg) or placebo determined randomly. During the day, cognitive testing, mood assessment (Profile of Mood States), and assessment of subjective (Stanford and Epworth Sleepiness Scales) and objective sleepiness (Multiple Sleep Latency Test – 3 naps) were performed. The complete CogScreen-Aeromedical Edition (CogScreen-AE) computerized cognitive battery assessed attention, memory, and reaction time among other factors. CogScreen-AE subtests were analyzed by throughput (correct responses/minute), accuracy, and speed (median reaction time to correct responses). All variables with sufficient data were combined in summary measures; two were discarded.

Results: Cognitive performance as assessed by overall throughput was significantly better (p=.018) following NADH than after placebo, after adjusting for baseline performance. Analysis of individual cognitive tests revealed that math throughput

(over)

 **New York-Presbyterian**
The University Hospitals of Columbia and Cornell

Columbia Psychiatry

Columbia Presbyterian
Medical Center
622 West 168th Street
New York, NY 10032
212-305-2599

The Allen Pavilion
5141 Broadway
New York, NY 10034
212-305-2599


Affiliate

New York State Psychiatric
Institute
1051 Riverside Drive
New York, NY 10032
212-543-5000

Weill Cornell Psychiatry

Payne Whitney Clinic
535 East 68th Street
New York, NY 10021
888-NYH-5700

Westchester Division
21 Bloomingdale Road
White Plains, NY 10605
888-NYH-5700







The International Press Reports on ENADA -NADH

Enzyme fights fatigue - study

WASHINGTON — A nutritional supplement based on an energy-giving natural enzyme can help in some cases of chronic fatigue syndrome, researchers will report today.

A team at Georgetown University in Washington tested the supplement, Enada, and found it helped as many as 72% of patients with the baffling condition.

More than 500,000 Americans have been diagnosed with chronic fatigue syndrome, and an estimated 2 million people believe they have it.

In the Georgetown study, approved by the U.S. Food and Drug Administration, Dr. Joseph Bellanti and colleagues said they tested 26 patients in the equivalent of a Phase II safety and efficacy trial.

For four weeks, half the patients got Enada and half got placebo.

For the next month, both groups got nothing, then the groups were switched — and the volunteers who got Enada the first time took a placebo for the next four weeks, while the second group got the supplement.

Neither group knew which they were getting at the time, placebo or supplement.

Writing in the *Annals of Allergy, Asthma and Immunology* to be published today, Bellanti's team reports that 31% of the patients said their symptoms got better while they took Enada, as opposed to 8% of those on placebo.

Then the researchers opened the trial, allowing all the volunteers to knowingly take Enada. After a year, 72% reported improvement.

Enada is the brand name of the company's version of a natural substance known as nicotinamide adenine dinucleotide, plus high-energy hydrogen (NADH).

It is a co-enzyme — the active part of the chemical reaction that enzymes produce in the body.

According to Menuco, the more NADH a cell has, the more energy it has.

The company hopes that can translate up to the level of a whole human being.

Unlike many supplement companies, Menuco went through some of the FDA protocols for testing. They were not required to.

In December, Hemispherx Biopharma Inc. applied for European Union approval of the first drug to treat chronic fatigue syndrome.

The drug, Ampligen, also is being tested for FDA approval. It consists of hydrocortisone, a synthetic version of one of the corticosteroid hormones produced by the adrenal gland.

Chronic fatigue syndrome is difficult to define, marked for the most part by an unexplained lack of energy.

Sometimes called myalgic encephalomyelitis, some doctors attribute it to psychological rather than physical causes.

Others say a virus, perhaps Epstein-Barr virus, may cause it, or perhaps an autoimmune disorder in which the body's immune system mistakenly turns against itself.

Newsweek



Clearing the Mental Fog

NEWSWEEK

A natural enzyme can help clear the mental fog that plagues many people with chronic fatigue syndrome. The enzyme, NADH, is a co-enzyme that helps produce energy in the body. It is also a natural substance that helps clear the mental fog that plagues many people with chronic fatigue syndrome.

It's a full-on regimen to sleep less. After staying up the 24 hours, volunteers received either a placebo or 20 mg of NADH. The placebo group had the worst time sleeping. The NADH group had the best time sleeping. The NADH group also had the best time staying awake.

Results from a 25-person trial are in. The NADH group had the best time sleeping. The NADH group also had the best time staying awake.

Newsweek - Dec. 2001 USA

ScienceBackground

NADH: Biological Rocket Fuel

By Gary D. Bivens, M.D., Ph.D.

If we need energy. Every living cell needs energy to survive.

The mitochondria are the powerhouses of the cell. They produce energy in the form of ATP (adenosine triphosphate). The mitochondria are the powerhouses of the cell. They produce energy in the form of ATP (adenosine triphosphate).



How NADH is Produced in Vivo

NADH is produced in the body from the breakdown of nicotinamide (vitamin B3) and ADP (adenosine diphosphate). Nicotinamide is a precursor of NADH from which it is synthesized in the body.

Functions/Applications of NADH

NADH is a co-enzyme that helps produce energy in the body. It is also a natural substance that helps clear the mental fog that plagues many people with chronic fatigue syndrome.

Wiener Medizinische Wochenschrift

Themenswerpunkt: „Flugmedizin aktuell“

Jahrgang 152 Heft 17/18 2002

Blackwell Verlag

Wiener Medizinische Wochenschrift - 2002 AU

NEWSWORTHY TRENDS

Supplement Can Help Boost Energy Levels

NEWSWORTHY TRENDS

A natural enzyme can help boost energy levels in people with chronic fatigue syndrome. The enzyme, NADH, is a co-enzyme that helps produce energy in the body. It is also a natural substance that helps clear the mental fog that plagues many people with chronic fatigue syndrome.

According to the Centers for Disease Control, more than 14 million Americans experience chronic fatigue syndrome, some of whom may be suffering from Chronic Fatigue Syndrome (CFS). This disorder causes overwhelming tiredness or lack of energy, and has no known cure.

ENADA is one of the first nutritional supplements to be tested using strict FDA and Drug Administration guidelines to determine its safety and effectiveness. Georgetown doctors found that 31 percent of the patients who took ENADA felt significantly relieved from their symptoms of fatigue.

According to a recent, national Gallup poll, seventy percent of Americans believe that the quality of their food is important to their health. The fact is, many Americans are not eating the right foods to support their health. The fact is, many Americans are not eating the right foods to support their health.

ENADA is the brand name for the only available, patented, absorbable NADH (nicotinamide adenine dinucleotide plus high-energy hydrogen). For over 20 years, researchers around the world have known that NADH, a natural co-enzyme, is critical to human health.

ENADA is a brand name for the only available, patented, absorbable NADH (nicotinamide adenine dinucleotide plus high-energy hydrogen). For over 20 years, researchers around the world have known that NADH, a natural co-enzyme, is critical to human health.

STUDIES CLARIFY BENEFITS FOR ATHLETES

Early studies found that NADH supplementation can ease the symptoms of brain fog and physical dysfunction found in patients suffering from chronic fatigue syndrome, Alzheimer's and Parkinson's disease. Recent research suggests that these same supplements can improve physical and mental performance in healthy people as well. In addition, no negative side effects have been reported.

In a study conducted at the New York Well-Cornell Medical Center, a group of 25 healthy volunteers were kept awake overnight and then given a series of mental tests the following day. These tests measured the speed and accuracy with which volunteers were able to think and solve problems under two separate conditions — after taking 20 mg of NADH and after taking placebo. "When the subjects took NADH, they performed more efficiently without experiencing any negative side effects," reports Margaret Melvin, Ph.D., the lead researcher of the study. In some cases, participants who took the NADH actually performed better than they had in a fully rested state.

Other research has shown that NADH enhances reaction times and performance quality of competitive athletes. In a study that was conducted at the University of Freiburg, endurance athletes who were kept on 30 mg of NADH daily for four weeks (10 mg three times per day) saw an average 7% increase in muscular energy — two given placebo. The subjects taking the NADH supplements also experienced increased efficiency in the body's utilization of oxygen.

"These results are unheard of when compared to any other supplement for the purpose of increasing energy and aerobic economy," says George Birkmayer, M.D., Ph.D., the Austrian researcher who first recognized the therapeutic applications of NADH. "NADH can be characterized as the rocket fuel for the body. The more NADH a cell has available, the more energy it can produce."

If NADH is present in every living cell, why not rely on food sources for it? Because naturally occurring NADH, found primarily in red meat and poultry, disintegrates rapidly during cooking and digestion, says Joseph Bellanti, M.D., a physician at the Georgetown University School of Medicine. People are particularly susceptible to depletion of NADH during periods of fatigue, stress, severe allergy or chronic infection, Bellanti explains.

NOT FOR CONTINUOUS USE

NADH doesn't make you hyper the way caffeine does, or give you the instant "zap" of a candy bar when a half-hour later you find yourself coming down. Instead, you get a boost in physical energy and cognitive performance, especially beneficial before a workout or meeting.

Recommended daily dosages for NADH vary from 5 to 30 mg, depending on such individual factors as weight, metabolism and desired energy levels. NADH is available in a long-acting form meant for ongoing use, as well as a quick-acting form that dissolves under the tongue and gives a shot of NADH to the body — a burst of energy that can be felt in as little as 20 minutes and lasts for five to six hours thereafter. According to Bellanti, his studies on patients with chronic fatigue syndrome indicate a cumulative increase in effectiveness after extended use of NADH.

Dr. Ray Siebelin, M.D., a physician who practices nutritional medicine in Marina Del Rey, Calif., and author of *Mind Over Stress* (St. Martin's Press, 2001), doesn't think that taking NADH on a long-term daily basis is a good idea. According to him, uninterupted use could create a tolerance level at which the body might cease to benefit from the positive effects of NADH. "I wouldn't recommend it as part of an ongoing daily regimen, but I do feel very comfortable recommending it for occasional use," he says.

Most sources suggest using it daily for periods of up to four continuous months, then taking a month off. An alternative is to take it only two or three times a week, or on those occasions when you need that extra boost in energy.

Additional clinical trials in the United States and other countries are exploring the full potential of NADH for improved health and athletic performance. In the meantime, its top-notch safety record and proven effectiveness clearly make NADH a nutrient to check out.

Leahly Singsap, a graduate of the Massachusetts Institute of Technology, is a freelance writer who lives in Los Angeles.

Physical Magazine - June 2003 USA

Wall Street Journal, Dec. 2001

-Washington Journal

-Der Kurier

-uvm.

In television covered by : ABC, CNN, NTV, RTL et al..

Our Tired Reporter Flight-Tests a Product To Combat Jet Lag

The Trip Is as Exasperating
As Science Can Devise:
An Unfun Game of Hearts

By CHRIS ADAMS

Staff Reporter of THE WALL STREET JOURNAL.
At about seven on a Saturday morn-
ing, I am one of 11 tired and slightly
irritable travelers walking off an Amer-
ica West red-eye from San Diego to Balti-
more. In the past six hours, we have had
flight delays and been subjected to elec-
tronic mind games at 30,000 feet. Now,
the one thing I want is a cup of coffee.

But caffeine isn't allowed. "I tell you, I
can smell Starbucks on a person's breath
from five yards away," warns a young re-
search assistant named Robert Sitarz,
who for 15 hours has watched everything
we put in our mouths.

We all are groggy, and that's the way
it's supposed to be. In the end we are
taken by van to a researcher's office in
northwest Washington, where about half
of us get our first dose of a dietary supple-
ment called NADH, the others a placebo.
We don't know who is getting what. The
idea is to see if NADH, which stands for
nicotinamide adenine dinucleotide hydro-
gen, mitigates the effects of jet lag.

Guinea-Pig Roundup

If so, it would be a welcome relief to
bicoastal executives—and a financial
boon to Menuco Corp., in New York,
which sells the nonprescription stuff un-
der the brand name ENADAlert and spon-
sored the research. Studies like these al-
low companies to plaster the phrase "clin-
ically proven" on their packaging. So Me-
nuco rounded up 35 guinea pigs, sub-
jected them to hassle-filled, cross-country
flights, and tested them every few hours
to see whose mental acuity breaks down
the fastest—the NADH users or the sugar-
pill poppers.

I am one of those guinea pigs. This
(yawn) is my story.

The ordeal starts the morning of the
Friday flight, when a group of 11 healthy
men and women, all at least 35 years old,
gather in the San Diego office of an oto-
neurologist named Erik Viirre.

Each of us leaves a urine sample and
listens to the rules: no caffeine, no alco-
hol, no sunlight. Our group is the third to
participate in the study, each under the
watchful eye of Mr. Sitarz. (The Wall
Street Journal paid my expenses, and I
didn't accept the \$225 participant's fee.)

Looming Mystery

The trial is overseen by researchers
from the University of California, San Di-
ego and Georgetown University School of
Medicine in Washington. Only after all
three groups are finished will researchers
"break the code" to see which pills each
subject got.

Nobody among us had heard about
NADH before. And, in truth, most of the
people recruited in San Diego see the ex-
periment pretty much as a free trip to
Washington.

The trip is west to east since jet lag is
worse flying in that direction. We're mak-
ing a stop in Phoenix to ensure that the
flights are as annoying as possible. We're
to arrive in Washington at daybreak Satur-
day—theoretically just in time to catch a
cab for a meeting with East Coasters who
have slept all night in their own beds. The
whole experiment, says Dr. Viirre, is de-
signed to mimic "the executive's lousy
business trip."

Once equipped with laptop computers,
we're promptly subjected to a battery of
Please Turn to Page A10, Column 1

Continued From Page A1

rapid-fire mind games. Accuracy and
speed are paramount. Quick: Is 6 + 7 - 9
greater or less than five? How about 9 - 5
+ 2?

The tests take 45 minutes and will be
repeated five times over a 24-hour period.
We also answer a series of questions about
our moods that make us feel like charac-
ters in "Snow White and the Seven
Dwarfs": Are we "happy," "grouchy,"
"drowsy," "gloomy," "furious,"

But the "money test," in the words of
Dr. Viirre, is a simple game. Shapes flash
on the computer and then fade away. Our
task is to hit "enter" each time a heart
pops onto the screen.

Sounds easy, but not after 10 minutes.
"This test is deliberately slow and bor-
ing," he warns us. The tests measure
subjects' lapses of attention, which can
be caused by "microsleep," in which my
mind could temporarily shut down even
though I am sitting in a chair, with my
eyes open. "You can imagine it'll be a lot
tougher at midnight," Dr. Viirre says.

During the test, my mind doesn't
switch off so far as I can tell, but it does
wander. Schuyler Grant, a 44-year-old
physicist from San Diego, begins counting
each flashing figure, eventually reaching
250 or so.

*'I think you're going to
get a few more 'grouchy'
remarks this time,' says
fireman Tom Layman.*

By 3 p.m., a few participants are
yawning madly. We are hustled onto vans
for a trip to the San Diego airport and the
flight to Phoenix. After we arrive
there, we're shuttled to a hotel for dinner
and more tests.

Tiramisti Snafu

As we start eating, there is a small
crisis: We have been served a dessert of
tiramisu.

"Don't eat that!" Mr. Sitarz commands.
Tiramisu has espresso in it.

A waiter swoops down and whisks
away the desserts, offering carrot cake in-
stead.

By 11 p.m., we're back at the airport,
only to find our departure is to be 90
minutes late. Most of the group sacks out
on airport chairs. Terrance Kwiatkowski,
a 35-year-old head and neck surgeon,
changes into workout clothes and walks
briskly around the airport.

We're back on the plane, finally, at 1:30
in the morning. As other passengers try to
sleep, we all fire up our laptops and per-
form the tests again. In the middle of it all
the flight attendants offer drinks that
most, but not all, of us are too busy to
order. By 7 a.m., Eastern time, we are
back in a shuttle van, heading to the Wash-
ington offices of Dr. Gary Kay.

As we zip down the parkway, Tom Lay-
man, a 49-year-old fire-department battal-
ion chief from a town just outside San
Diego, turns to Mr. Sitarz: "I think you're
going to get a few more 'grouchy' remarks
this time," he says.

Once in the office, Dr. Kay breaks open
a case of vials. We each, as instructed, let
four little pills dissolve under our tongues.

Rousing Fernando

Then we wait. Then we test. Then we
wait some more—and we watch. While pre-
vious groups had been offered a sedate
selection of "National Geographic" videos,
we are given something a little more
lively: "Austin Powers: The Spy Who
Shagged Me." A few of us laugh at the
outrageous gags, while most just stare
blankly at the screen, and at least three
nod off.

"Fernando," somebody calls out to one
of the participants. No response. Fernando
is fast asleep, his chin resting heavily on
his hand.

"Fernando, wake up." No reaction.

"Fer-naaaan-do." Still nothing.

"I have a sneaking suspicion Fernando
got the placebo," offers Mr. Layman, the
fire chief.

A few minutes later, Fernando's chin
slips off his hand, and his head drops to-
ward his knees.

By 2 p.m., the final test battery is com-
plete. I am pretty sure my test-taking per-
formance has been pretty consistent through-
out the 24 hours; I guess it should have been
because later, when the code is broken, I
learn that I was indeed given NADH.

Science and Anecdote

So did the stuff work? Well, the com-
pany's news release, due out Friday, says the
NADH group "achieved significantly bet-
ter performance on tests of thinking and
skilled motor activity" and showed a
"trend to be less sleepy than subjects who
received placebo."

But a scientist's standard for statisti-
cal "significance" is more rigorous than
my subjective impression. Among the
participants in my group, for example
nobody felt noticeably different after tak-
ing the pills. (The researchers say that's
common; the idea is to restore normal
performance, not to jazz anybody up.)

As for the numbers, Drs. Kay and Vi-
irre note, in their article on the research,
there were differences in the NADH and
placebo groups.

On a test of "working memory," both
the groups posted 93% accuracy during the
first test, in San Diego. On the morning
test in Washington (taken one hour after
getting the pills), the performance di-
verged—down to 91% for the control group,
up to 95% for the NADH group. A few hours
later, on the last test, the placebo group
was 94% accurate, the NADH group 95%.

On the "money test"—the flashing
hearts—the morning test showed no differ-
ences (members of the placebo group each
averaged 1.6 errors, the NADH takers 1.7,
out of 45 possible "targets.") The after-
noon test showed the placebo group mak-
ing 2.3 errors, on average, while the
NADH group made 1.1.

An "error of omission" can be impor-
tant. Says Dr. Viirre: "It reminds me of
the air-traffic controller who says, 'Gee
boss, I got the last 100 planes in, but I just
missed that one.'"

As for the "trend to be less sleepy," it
wasn't strong enough to be statistically
significant. Nor was the mood test, which
showed almost no difference between the
placebo and NADH groups.

Even so, the results were good enough
for Menuco, which says it had about \$20
million in retail sales of NADH, its only
product, last year. The words "clinically
proven relief for jet lag" have already
crept into its pitch.









Attention Deficit Hyperactivity Disorder (ADHD)

Single Positron Emission
Computer Tomography
(SPECT – Scans)

before and 2 weeks after

ENADA® (quick acting NADH)



SPECT Scan of a
22 year old
student with
ADHD **before**
ENADA

A reduced oxygen
metabolism can
be seen

SPECT Scan of a
22 year old
student with
ADHD
2 weeks after
ENADA:

The oxygen
metabolism
became normal

The 2 most frequently asked questions about **ENADA®**

- (1) How safe is **ENADA** ?
- (2) Are there any side effects?

How safe is

ENADA®

**Documents
submitted to
the FDA**





The maximum tolerated dosage
of **NADH** is
500 mg / kg bodyweight

In other words, a person
with 70 kg bodyweight can
tolerate 35000 mg **NADH** or
7000 tablets ENADA 5mg



ENADA - NADH is one of the safest food supplement

- Long-term (6 month) safety tests in rats showed 15 mg per day per kg bodyweight is tolerated with no side effects
- 15 mg per kg corresponds to 1050 mg / day for a 70 kg subject.
- 1050 mg correspond to 105 tablets of **ENADA (10 mg NADH)**



No side effects have been observed

- In 6 GCP and FDA approved double blind, placebo controlled studies
- in open label studies with more than 1000 patients
- More than 500,000 consumers taking **ENADA** regularly since more than 5 years have not reported any side effects



Does **ENADA** interfere
with other drugs ?

Many subjects of the studies
were taking antihypertensive
antidepressive and/or
antihistaminic drug

No interference or side effects
were observed

Suggested daily dosages for

ENADA®



Suggested daily dosage for **ENADA**

- For more energy: 1 –2 tablets **ENADA 5mg**
- For chronic fatigue: 2 – 4 tablets **ENADA 5mg**
- After sleep deprivation: 1 – 2 tablets **ENADA 10mg (= quick acting ENADA)**

Suggested daily dosage for **ENADA**

- After travelling or Jet Lag: 1 – 2 tablets
10mg Performance (= quick acting ENADA)
- For athletic performance: 2 – 4 tablets
20mg Mojo (=quick acting ENADA)

Experience of

ENADA[®]

Consumers

Consumer Responses

selected from over 900 unsolicited letters

- „Grateful and amazed with energy and stamina ENADA gives me“
- „Great, Great, Great“
- „Stunning improvement in mental&physical energy and endurance“
- „Extraordinary, fantastic“
- „Feel stronger and more sexually able“

Consumer Responses

selected from over 900 unsolicited letters

- „As a nutritional consultant I have tried every product the industry has to offer, nothing remotely compares to the dynamic power of ENADA. WOW! Thank you.“
- „Great stuff !!“
- Mental alertness much improved. Energy vastly improved after 1 month“

DR. ATKINS in his book “VITA-NUTRIENT SOLUTION”

- Page 269:
- “In this book I have not been making product recommendations by brand name, but as this writing I have found only one effective form of NADH ,
the NADH made with
Dr. Birkmayer’s process

Earl Mindell in his “SUPPLEMENT BIBLE”

- page 110:
- **POSSIBLE BENEFITS:**
- Protects against brain aging.
- Relieves symptoms of Alzheimer’s and Parkinson’s disease
- Enhances ability to work out
- May increase memory and ability to concentrate



Insist on Solid
Scientific Evidence
of the Efficacy of
Nutritional
Supplements...
Before You Buy
Them



More information on **ENADA[®] NADH**

<http://www.enadh.com/>

<http://www.enadastudies.com/>